As KRAS and BRAF mutations are found in approximately 40% and 10% of human colorectal cancers (CRCs), respectively, the therapeutic use of vitamin C in treating patients with colorectal cancer presenting such type of mutations seems to be rational [91]. The gene discussed is KRAS; the disease is colorectal cancer.